Boston Scientific Built a $20 Billion Business From Smaller Incisions

Boston Scientific makes the sort of objects most people hope never to see and may owe their lives to anyway. A mesh implant seals a pouch in the heart where clots can form. A catheter delivers electric fields that interrupt an abnormal rhythm. A flexible scope travels into the urinary tract and reports pressure while a second machine adjusts the flow of fluid. These are not consumer products. They are instruments handled by specialists in bright rooms, often while the patient is awake, sedated or home the same day.

The company’s organizing idea predates its name. In the 1960s, inventor Itzhak Bentov helped develop steerable catheters at Medi-Tech. John Abele saw that a tube threaded through the body could be more than plumbing: it could carry tools to places surgeons once reached through a large incision. In 1979, Abele and Peter Nicholas formed Boston Scientific to acquire Medi-Tech and spread that idea. Their goal was practical - medical options that were more accessible, less costly and less traumatic.

Today Boston Scientific is based in Marlborough, Massachusetts, and operates at a scale the founders could hardly hide under a lab coat. It reported $20.074 billion in 2025 sales, about 59,000 employees and commercial representation in 127 countries. The company estimates that its technologies treated more than 48 million patients that year. It spent about $2 billion on research and development and launched roughly 100 products. That is almost two launches a week, from a business whose products can require years of engineering, trials, regulatory review and physician training.

A route into the body becomes a route to market

Boston Scientific’s portfolio can look like an unruly equipment drawer: balloons, stents, scopes, pacemakers, defibrillators, ablation catheters, spinal cord stimulators, stone-removal tools and embolization products. The order appears when you look at how they are used. Most belong to interventional medicine, where a physician navigates through a vessel, a natural opening or a small puncture to diagnose or treat disease without conventional open surgery.

Consider FARAPULSE. The system treats atrial fibrillation, a common irregular heart rhythm, by delivering brief electric fields through a catheter. Those fields create targeted lesions in cardiac tissue. Unlike older thermal methods that burn or freeze, pulsed field ablation is designed to affect heart tissue selectively. Boston Scientific won U.S. approval for FARAPULSE in 2024 and expanded its labeling in 2025 to include certain patients with persistent atrial fibrillation. The product became a major contributor to growth in the company’s electrophysiology business.

WATCHMAN solves a different problem in some patients with non-valvular atrial fibrillation. The implant closes the left atrial appendage, a small pocket where blood can pool and clots can form. For eligible patients, that creates a non-drug path to reducing stroke risk. Boston Scientific does not merely sell a plug. It supports a procedure, a referral pathway, patient education, clinical studies and follow-up. The difference matters because a medical device succeeds only when clinicians trust it, hospitals can pay for it and patients can reach the right specialist.

The product is only half the product

The economic customer is usually a hospital, clinic, ambulatory center, purchasing group or distributor. The user is a specialist: an electrophysiologist, interventional cardiologist, gastroenterologist, urologist, radiologist, oncologist, pain physician or surgeon. The patient is the beneficiary and often the least involved in choosing the brand. That split makes medtech a peculiar business. Marketing cannot create demand by itself. Clinical evidence, regulatory status, reimbursement, training, supply reliability and a representative who understands the procedure all have to arrive together.

Boston Scientific makes money from implants and reusable systems, but also from the disposable instruments and accessories consumed during procedures. That mix ties revenue to procedure volume. An installed platform can pull through recurring purchases, while a trusted sales channel makes it easier to introduce the next catheter or accessory to the same department. The company organizes the whole operation into Cardiovascular and MedSurg reporting segments, with eight core businesses beneath them.

Single-use scopes show the playbook at its most literal. The EXALT Model D duodenoscope and LithoVue ureteroscope arrive sterile and avoid the reprocessing cycle required by reusable scopes. Hospitals trade one set of costs and waste considerations for another, while care teams gain predictable availability. The 2026-cleared Asurys fluid system extends LithoVue into a paired workflow: it can regulate irrigation using pressure data from the scope, helping the physician balance a clear view with pressure inside the kidney.

Research, acquire, repeat

Internal research is one engine. Acquisitions are the other. The company began buying portfolio gaps in 1980, less than a year after its formation. The pattern continues. Axonics, acquired in 2024 for about $3.4 billion net of cash, added devices for urinary and bowel dysfunction. Silk Road Medical added a minimally invasive approach to carotid artery disease. Cortex brought cardiac mapping. Bolt Medical added intravascular lithotripsy, which uses acoustic pressure waves to fracture calcium inside diseased arteries. Intera Oncology added a pump for delivering chemotherapy to liver tumors.

In January 2026, Boston Scientific agreed to buy Penumbra in a cash-and-stock transaction carrying an enterprise value of roughly $14.5 billion. If completed, the deal would add mechanical thrombectomy and neurovascular products, taking the company into procedures that remove clots and treat diseases of the brain’s vessels. In May, it invested $1.5 billion for about 34 percent of MiRus and an exclusive option on that company’s transcatheter aortic valve business. These are not random excursions. They add another access route, anatomy or procedure to a commercial machine already calling on many of the same hospitals.

Where the company fits

Boston Scientific sits among the large diversified medtech companies, but it does not try to own every hospital category. Medtronic and Abbott meet it in cardiac rhythm, electrophysiology and vascular care. Johnson & Johnson’s Biosense Webster is a force in heart-rhythm mapping and ablation. Edwards Lifesciences is prominent in structural heart. Olympus competes in endoscopy; Stryker, Cook Medical, Becton Dickinson and focused specialists overlap elsewhere. The contests happen product by product and procedure by procedure.

Its distinction is not that rivals lack clever devices. It is the combination of breadth within interventional specialties and the infrastructure around the object: clinical programs, regulatory teams, manufacturing, field support, reimbursement resources and a global route to physicians. That system can turn a promising technology from a small acquired company into a category sold across many markets. It can also magnify mistakes. Device recalls, disappointing trial results, reimbursement changes and integration problems travel through the same network. In healthcare, scale is leverage and responsibility at once.

The latest numbers show both momentum and exposure. Second-quarter 2026 sales were $5.442 billion, up 7.5 percent as reported and 7 percent organically from a year earlier. Cardiovascular grew faster than MedSurg. The company also lowered its full-year growth outlook after a rapid 2025, a reminder that procedure markets, product cycles and clinical data do not compound in a straight line. Boston Scientific’s market value was about $68.5 billion in late July 2026, after a sharp reset from prior highs.

For physicians, the portfolio is a menu of ways to reach difficult anatomy and treat it with less disruption. For hospitals, it offers systems, supplies, training and support from one established vendor. For patients, the practical benefit can be a smaller incision, a shorter recovery, an alternative to long-term medication or a treatment where conventional surgery is not the best fit. None of those outcomes is automatic; device choice belongs in a clinical conversation. But the company’s contribution to medicine is easy to state. It keeps asking whether the path to treatment can be narrower.

That question has survived every expansion of the business. Peter Nicholas once used another to keep colleagues uneasy: “How do we stay small as we grow big?” Boston Scientific is now far too large to answer literally. The more useful answer is architectural. Small teams find an unmet need. Small devices enter the body. Small procedural improvements accumulate across millions of cases. The corporation around them is enormous, but the idea at its center still fits through a catheter.